A trial of pexastimogene devacirepvec [Pexa-Vec] in combination with immune checkpoint inhibitors in cancer patients
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Pexastimogene devacirepvec (Primary) ; Durvalumab; Tremelimumab
- Indications Colorectal cancer
- Focus Adverse reactions
- 01 Jul 2017 Planned initiation date changed from 6 Jul 2017 to 7 Jul 2017.
- 30 Jun 2017 Status changed from planning to not yet recruiting.
- 30 Mar 2015 New trial record